Linde M. Van Veenendaal

Dr. Linde M. Van Veenendaal


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2018 in Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
LVLinde M. Van Veenendaal
Linde M. Van Veenendaal
AAAlexander C.J. van Akkooi
Alexander C.J. van Akkooi
CVCees Verhoef
Cees Verhoef
DGDirk Jan Grünhagen
Dirk Jan Grünhagen
WKW. Martin C. Klop
W. Martin C. Klop
MTMargot E. T. Tesselaar
Margot E. T. Tesselaar
Background: Merkel cell carcinoma (MCC) is a rare and aggressive neuroendocrine carcinoma of the skin.Aim: To describe clinical outcome and prognostic factors of MCC patients in two expert‐centers.Method: Patients with histologically confirmed MCC in 1990‐2014 were included. Data on patient, tumor characteristics and treatment were retrospectively collected.Results: A total of 351 Patients were evaluated, 153 (44%) males, median age 74 years (range 28‐94). Median follow‐up time was 28 months (IQR 13‐58). Median primary tumor size was 17 mm (range 2‐135). At time of diagnosis 112 (32%) patients had lymph node metastases. The cohorts′ 5‐year overall survival (OS) was 58%. Using a competing risk analysis the 5‐year relapse and MCC related death was 42% and 22%. Adjuvant radiation therapy (XRT) was associated with reduced recurrence (SDH 0.54; CI 0.3‐0.9). Nodal involvement (SDH 2.7; CI 1.1‐6.6) and the male gender were associated with higher MCC related death (SDH 3.1; CI 1.2‐7.9)Conclusion: In a large cohort a low MCC related death, in the presence of a low OS was seen. This indicates that a significant number of MCC patients die due to other causes than MCC. Adjuvant XRT was associated with relapse. Male gender and nodal metastasis were associated with MCC related death.

15 September 2020 in Histopathology
Verified
Journal Article
Closed access
PDF file
KSKris G. Samsom
Kris G. Samsom
SLSonja Levy
Sonja Levy
LVLinde M. Van Veenendaal
Linde M. Van Veenendaal
PRPaul Roepman
Paul Roepman
LKLiudmila L. Kodach
Liudmila L. Kodach
JBJosé G. van Den Berg
José G. van Den Berg

26 September 2017 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
LHL.D. de Hosson
L.D. de Hosson
LVLinde M. Van Veenendaal
Linde M. Van Veenendaal
YSY. Schuller
Y. Schuller
WZW.T. Zandee
W.T. Zandee
WHW.W. de Herder
W.W. de Herder
AWAnnemiek Walenkamp
Annemiek Walenkamp
Assessment of clinical benefit of systemic treatments of rare diseases including gastroenteropancreatic neuroendocrine tumours (GEP-NET) is challenging. Recently several tools have been developed to grade the clinical benefit of cancer drugs. The European Society for Medical Oncology (ESMO) has developed the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS). The American Society of Clinical Oncology (ASCO) has developed and revised the ASCO framework consisting of the Net Health Benefit (NHB) score juxtaposed against the costs of the treatment. In this review, we graded systemic treatments for GEP-NET patients with both frameworks. The electronic databases (PubMed and EMBASE) were searched for papers reporting comparative trials, conducted in adult GEP-NET patients in the English language. Papers were assessed according to the ESMO-MCBS and the NHB part of the ASCO revised Framework (NHB-ASCO-F) by four independent assessors, and discrepancies were discussed. The search yielded 32 trials of which 6 were eligible for grading with the ESMO-MCBS resulting in scores of 2 or 3. Eight trials were eligible for grading with the NHB-ASCO-F, resulting in scores between 37.6 and 57.4. Trials that were not primary assessable by the tools were analysed separately. Consensus between assessors was reached in 68% of trials with the ESMO-MCBS and in 23% of trials with the NHB-ASCO-F. The currently used systemic treatments for GEP-NET patients had low scores according to the NHB-ASCO-F and none could be graded as meaningful clinical beneficial according to the ESMO-MCBS. Despite the low incidence, the heterogeneous patient population and relatively long natural course of NET, future studies on new treatment modalities should aim for high clinical benefit outcomes.

3 August 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SLSonja Levy
Sonja Levy
LVLinde M. Van Veenendaal
Linde M. Van Veenendaal
CKCatharina M. Korse
Catharina M. Korse
EBEmilie C.H. Breekveldt
Emilie C.H. Breekveldt
WVWieke H.M. Verbeek
Wieke H.M. Verbeek
MTMargot E.T. Tesselaar
Margot E.T. Tesselaar
Neuroendocrine tumours of the small intestine (SI-NETs) are rare and heterogeneous. There is an unmet need for prognostication of disease course and to aid treatment strategies. A previously developed nomogram based on clinical and tumour characteristics aims to predict disease-specific survival (DSS) in patients with a SI-NET. We aimed to validate the nomogram and identify predictors of survival. Four hundred patients with a grade 1 or 2 SI-NET were included, between January 2000 and June 2016. Predicted 5- and 10-year survival was compared to actual DSS. Multivariable analysis identified predictors for actual DSS. We found that in low-, medium- and high-risk groups 5-year nomogram DSS vs. actual DSS was 0.86 vs. 0.82 (p < 0.001), 0.52 vs. 0.71 (p < 0.001) and 0.26 vs. 0.53 (p < 0.001), respectively. Ten-year nomogram DSS vs. actual DSS was 0.68 vs. 0.69 (p < 0.001), 0.40 vs. 0.50 (p < 0.001) and 0.20 vs. 0.35 (p < 0.001), respectively. Age, WHO-performance score of 2, Ki-67 index ≥10, unknown primary tumour, CgA > 6x ULN and elevated liver tests were identified as independent predictors for a worse DSS. This shows that the nomogram was able to differentiate, but underestimated DSS for patients with a SI-NET. Improvement of prognostication incorporating new emerging biomarkers is necessary to adequately estimate survival.

1 November 2017 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
LVLinde M. Van Veenendaal
Linde M. Van Veenendaal
MMM.F. Madu
M.F. Madu
MTM.E.T. Tesselaar
M.E.T. Tesselaar
Cornelis VerhoefCornelis Verhoef
Cornelis Verhoef
DGDirk Jan Grünhagen
Dirk Jan Grünhagen
AAAlexander C.J. van Akkooi
Alexander C.J. van Akkooi

18 February 2014 in Geriatric Orthopaedic Surgery & Rehabilitation
Verified
Journal Article
Open access
LVLinde M. Van Veenendaal
Linde M. Van Veenendaal
GKGijs de Klerk
Gijs de Klerk
DVDetlef van der Velde
Detlef van der Velde
Introduction: Bone metastases are frequently seen in patients with malignancies, but only 0.007% to 0.3% of these metastases are located in the hand or foot. In 16%, the metastasis is the first manifestation of a malignancy. These acrometastases have a poor prognoses with a median survival of 6 months. Treatment is usually palliative and consists of radiation or amputation. Case Description: An 83-year-old woman was seen with pain and swelling of the right middle finger since 3 months. A radiograph of this finger showed a lytic lesion of the proximal phalanx. A metastasis, primary bone tumor, or osteomyelitis was considered. Because of a radically resected colon carcinoma in patient’s medical history, the carcinoembryonic antigen level was analyzed and proved to be elevated. Computed tomography scan of thorax and abdomen showed 2 (primary) pulmonary tumors with mesenteric metastases. Patient refrained from further analysis and treatment of these lung tumors. However, because of persistent pain the right middle finger was amputated. Pathological examination of the finger confirmed the diagnosis of an adenocarcinoma most likely to be a metastasis of lung cancer. Lung cancer is in most cases responsible for metastases in the hand. Conclusion: Acrometastasis may be the first manifestation of malignancy. Given the poor prognosis, early diagnosis is important to offer adequate treatment. Delay of appropriate treatment can adversely affect the quality of life in these often preterminal patients. This case report could contribute to a (more) rapid recognition of acrometastases as patients with acrometastases are often presented to specialists who do not frequently deal with cancer.